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Many cases of bronchiolitis are caused by the respiratory syncytial 
virus (RSV), which was first identified in 1956 as causing illness in 
humans. Despite ongoing efforts since the 1960s to develop an RSV 
vaccine, it has remained elusive. The RSV vaccine research agenda 
experienced a major setback after the increased susceptibility to 
severe RSV disease and death in children who received the first 
formalin-inactivated vaccine in the 1960s. Only in the mid-1980s 
was the search for an RSV vaccine re-ignited. Alternative approaches 
to developing this vaccine included attempts at attenuation of RSV, 
which generally resulted in vaccine candidates that were either too 
reactogenic or too attenuated. Furthermore, the targeted approach 
of using the conserved fusion protein (F-protein), although showing 
some promise in older persons with underlying medical conditions, 
was not developed into a potential candidate for young children, for 
whom the need is greatest.  
The F-protein target, however, was used to develop palivizumab, 
a humanised monocloncal antibody that has been shown – since the 
mid-1990s – to prevent RSV lower respiratory tract infection in young 
children with underlying risk factors. However, the widespread use 
of palivizumab has been impeded by the logistics to provide monthly 
intramuscular injections for 4 - 5 months of the year while the RSV 
circulates in temperate climates, and by its cost, which makes it 
unaffordable and not cost-effective in most countries. Also, as it is only 
targeted at high-risk children, it misses prevention of RSV in otherwise 
healthy children, who comprise 70% of all RSV hospitalisations. 
The prospect of more affordable and efficacious vaccines to 
prevent RSV illness in the majority of children has changed over 
the past 5 years. This includes the successful development of a 
re-engineered F-protein monoclonal antibody that has an extended 
half-life, which would allow for a single dose to provide protection 
against RSV illness for the duration of the RSV season (4 - 5 months). 
The first safety and antibody kinetics study of this monoclonal 
antibody was recently concluded. Moreover, a number of other RSV 
vaccine candidates (>20) are currently being researched in clinical 
trials.[1] These include the next generation of re-engineered live 
attenuated RSV vaccines, vector-based vaccines, F-protein-based 
subunit vaccines, including the use of nanoparticle technology or 
targeting the prefusion epitopes of the F-protein.[2,3] 
The strategy to optimise the protection of young infants, consi-
dering that the mean age for contracting RSV is usually 4 - 5 months 
and that these children might be too young to benefit from active 
vacci nation, has also recently undergone a paradigm shift. In 
particular, it has been accepted that pregnant women may potentially 
be vacci nated to protect their infants against illness during the first 
3 - 4 months of life by enhancing transplacental acquisition of vac-
cine-induced maternal antibody. This strategy not only contributed 
to the control of neonatal tetanus globally, but has more recently 
been shown to prevent influenza and pertussis in young infants in 
whom the burden of severe disease is the greatest.[4,5] Accordingly, 
the first studies of the nanoparticle RSV F-protein vaccine candidate 
in pregnant women were recently completed, and a multicentre safety 
and efficacy trial is currently underway in pregnant women, also 
at multiple sites in South Africa. Furthermore, at least three other 
vaccines, also targeted at the F-protein, are likely to enter into clinical 
trials in pregnant women during the next 5 years. 
Although vaccination of pregnant women is likely to benefit their 
young infants, this will probably need to be coupled with other 
vaccination strategies in children to provide protection until at least 
12 - 24 months of age. Vaccination strategies specifically targeted at 
children are also being pursued over and above passive immunisation 
with a monoclonal antibody. This could include using the same 
vaccine candidates being evaluated in pregnant women and live 
attenuated vaccines, especially in older infants. 
Therefore, while RSV currently remains the leading cause of 
hospitalisation for lower respiratory tract infection globally (~30 - 
40% of all cases), it is hoped that the next 10 years will see the face of 
paediatric practice change once again, if some of the current passive 
and active RSV vaccine candidates are licensed. The challenge for 
low- and middle-income countries would be to ensure that any 
such vaccines are affordable and timeously implemented into public 
immunisation programmes to reduce RSV-associated hospitalisation 
sequelae such as recurrent wheezing and death. 
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